MX2025007584A - Sales y formas solidas del intermedio sonrotoclax - Google Patents
Sales y formas solidas del intermedio sonrotoclaxInfo
- Publication number
- MX2025007584A MX2025007584A MX2025007584A MX2025007584A MX2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A
- Authority
- MX
- Mexico
- Prior art keywords
- sonrotoclax
- salts
- solid forms
- processes
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En este documento se describen sales y formas sólidas del intermedio sonrotoclax y procesos para su preparación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022142316 | 2022-12-27 | ||
| PCT/CN2023/141989 WO2024140692A1 (en) | 2022-12-27 | 2023-12-26 | Salts and solid forms of sonrotoclax intermediate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025007584A true MX2025007584A (es) | 2025-09-02 |
Family
ID=91716479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025007584A MX2025007584A (es) | 2022-12-27 | 2025-06-26 | Sales y formas solidas del intermedio sonrotoclax |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250320209A1 (es) |
| EP (1) | EP4642776A1 (es) |
| JP (1) | JP2026503230A (es) |
| KR (1) | KR20250127312A (es) |
| CN (1) | CN119301117A (es) |
| AU (1) | AU2023416871A1 (es) |
| IL (1) | IL321700A (es) |
| MX (1) | MX2025007584A (es) |
| TW (1) | TW202434586A (es) |
| WO (1) | WO2024140692A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112437772B (zh) * | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| MX2023014275A (es) * | 2021-06-02 | 2024-03-06 | Beigene Switzerland Gmbh | Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2. |
| TW202400163A (zh) * | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 使用bcl-2抑制劑治療髓性惡性腫瘤之方法 |
-
2023
- 2023-12-26 WO PCT/CN2023/141989 patent/WO2024140692A1/en not_active Ceased
- 2023-12-26 EP EP23910615.6A patent/EP4642776A1/en active Pending
- 2023-12-26 IL IL321700A patent/IL321700A/en unknown
- 2023-12-26 AU AU2023416871A patent/AU2023416871A1/en active Pending
- 2023-12-26 TW TW112150831A patent/TW202434586A/zh unknown
- 2023-12-26 CN CN202380043279.9A patent/CN119301117A/zh active Pending
- 2023-12-26 KR KR1020257024868A patent/KR20250127312A/ko active Pending
- 2023-12-26 JP JP2025537587A patent/JP2026503230A/ja active Pending
-
2025
- 2025-06-26 US US19/250,670 patent/US20250320209A1/en active Pending
- 2025-06-26 MX MX2025007584A patent/MX2025007584A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL321700A (en) | 2025-08-01 |
| TW202434586A (zh) | 2024-09-01 |
| KR20250127312A (ko) | 2025-08-26 |
| WO2024140692A1 (en) | 2024-07-04 |
| CN119301117A (zh) | 2025-01-10 |
| US20250320209A1 (en) | 2025-10-16 |
| JP2026503230A (ja) | 2026-01-28 |
| AU2023416871A1 (en) | 2025-08-14 |
| EP4642776A1 (en) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY209340A (en) | Egfr inhibitor for the treatment of cancer | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2022015597A (es) | Formas en estado solido de ciantraniliprol. | |
| WO2022192414A3 (en) | Synthesis of omecamtiv mecarbil | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MX2021008002A (es) | Sales nuevas y forma polimorfica del acido bempedoico. | |
| MX2025003937A (es) | Formas cristalinas de un agente anti-sars cov-2 | |
| MX2025012200A (es) | Sintesis de inhibidores de ras | |
| MX2023006512A (es) | Método para preparar pralsetinib. | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| PH12021550403A1 (en) | Process of making calcium alpha-ketoglutarate | |
| ZA202103228B (en) | Crystal forms of an alk2 inhibitor | |
| EP4480538A3 (en) | Solid state forms of mavacamten and process for preparation thereof | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX2025007384A (es) | Inhibidores de malt1 | |
| WO2020018751A9 (en) | Methods and kits of using an implant for tissue repair | |
| MX2025008454A (es) | Inhibidores de mptp | |
| MX2025013242A (es) | Quinoxalinas sustituidas | |
| MX2024014450A (es) | Composiciones de genoterapia y metodos de uso de las mismas | |
| MX2025007548A (es) | Pirroloquinazolinonas espirociclicas sustituidas y piperidinoquinazolinonas espirociclicas sustituidas | |
| IL279168B (en) | A process for the preparation of eribulin | |
| WO2021118924A3 (en) | Compositions and methods for the prevention and treatment of hearing loss | |
| EP4353230A3 (en) | Solid state forms of asciminib and process for preparation thereof | |
| MX2022013961A (es) | Sintesis de productos intermedios de sulfonamida. | |
| JOP20230034A1 (ar) | مثبطات إفراز البروتين |